We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Low-Cost and Fast COVID-19 Test Detects SARS-CoV-2 from Pool of Gargle Lavage Samples in One Hour

By LabMedica International staff writers
Posted on 08 Mar 2021
Researchers have developed a low-cost and fast method to detect COVID-19 infection from a pool of gargle lavage samples.

Researchers of the Max Planck Institute for Evolutionary Anthropology (Leipzig, Germany) have developed improved protocols for the detection of SARS-CoV-2, and the method can detect a positive sample in a pool with 25 uninfected samples in less than one hour. More...
In order to monitor and contain the spread of SARS-CoV-2, it is necessary to test large numbers of people on a regular basis in decentralized settings. Quantitative real-time polymerase chain reaction (qPCR) is the most widely used diagnostic method to detect RNA viruses such as SARS-CoV-2. However, it requires expensive laboratory equipment and global shortages of reagents for RNA purification has increased the need to find simple but reliable alternatives.

One alternative to the qPCR technology is RT-LAMP (reverse transcription loop-mediated isothermal amplification). This test amplifies the desired target sequences of the virus at a constant temperature, using minimal equipment as compared to qPCR. In 2020, RT-LAMP was adapted for the detection of SARS-CoV-2. It was also shown that instead of a swab, which many people find unpleasant, it can be performed on gargle lavage samples.

Max Planck researchers have now developed an improved colorimetric RT-LAMP assay, called Cap-iLAMP (capture and improved loop-mediated isothermal amplification), which extracts and concentrates viral RNA from a pool of gargle lavage samples. After a short incubation, the test result - orange/red for negative, bright yellow for positive - can be interpreted visually or by using a freely available smartphone app. The improved testing method outperforms previous similar methods.

“Cap-iLAMP drastically reduces false positives and single infected samples can be detected in a pool among 25 uninfected samples, thus reducing the technical cost per test to only about 1 Euro per individual”, said senior author Stephan Riesenberg, a researcher at the Max Planck Institute for Evolutionary Anthropology. “Our method overcomes problems associated with standard RT-LAMP and could also be applied to numerous other pathogens.”

Related Links:
Max Planck Institute for Evolutionary Anthropology


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.